𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Hepatitis E virus infection in patients infected with the human immunodeficiency virus

✍ Scribed by Mamadou Kaba; Hervé Richet; Isabelle Ravaux; Jacques Moreau; Isabelle Poizot-Martin; Anne Motte; Corinne Nicolino-Brunet; Françoise Dignat-George; Amélie Ménard; Catherine Dhiver; Philippe Brouqui; Philippe Colson


Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
212 KB
Volume
83
Category
Article
ISSN
0146-6615

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Hepatitis E virus (HEV) is a newly‐identified causative agent of acute and chronic hepatitis in severely immunocompromized patients. The present study sought to assess the prevalences of past, recent, on‐going, and chronic HEV infections in patients infected with human immunodeficiency virus (HIV) in Marseille, South‐eastern France, and to determine if they were correlated with the patients' immunological status or with cirrhosis. Anti‐HEV IgG and IgM and HEV RNA testing were concurrently performed on the plasma from 184 patients infected with HIV, including 81 with a CD4+ T‐lymphocyte count (CD4 count) <50 cells/mm^3^ and 32 with a cirrhosis. Prevalence of anti‐HEV IgG and IgM was 4.4% (8/184) and 1.6% (3/184), respectively. Past, recent, and on‐going infections were observed in 3.3% (6/184), 1.6% (3/184), and 0.5% (1/184) of the patients, respectively. Anti‐HEV antibodies prevalence did not differ significantly according to CD4 count, cirrhosis, sex, age, mode of HIV transmission, and infection with hepatitis B or C virus. Anti‐HEV IgG seroreversion was observed in two patients. The patient whose plasma tested positive for HEV RNA had a CD4 count <50 cells/mm^3^; HEV genotype was 3f. In this patient, longitudinal testing showed HEV RNA positivity during a 10‐month period, indicating chronic HEV infection; in contrast, anti‐HEV IgG never tested positive. Further studies are needed to evaluate the performance of commercial HEV serological assays in patients infected with HIV and to assess the actual incidence, prevalence, and outcome of HEV infection in this special group of patients. HEV RNA testing is necessary for such purposes. J. Med. Virol. 83:1704–1716, 2011. © 2011 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Autoantibodies in human immunodeficiency
✍ Antonio Montero; Adria G. Giovannoni; Marcelo A. Fernández; Bernardo Pons-Estel; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 363 KB 👁 2 views

## Autoantibodies in human immunodeficiency virusinfected patients with and without concurrent hepatitis C infection Infections caused by human immunodeficiency virus (HIV) and hepatitis C virus (HCV), 2 blood-transmitted and frequently coinfecting agents, have been associated with autoantibody pr

Prevalence of hepatitis C virus antibodi
✍ Paul H. Hayashi; Neil Flynn; Stephen A. McCurdy; I. K. Kuramoto; Paul V. Holland 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 414 KB 👁 1 views

## Abstract A study was undertaken to determine the prevalence and risk factors for serological evidence of hepatitis C virus (HCV) infection in patients infected with the human immunodeficiency virus (HIV). Tests for anti‐HCV antibody were carried out by enzyme‐linked immunoassay (EIA) on 101 HIV‐

Cervical cancer in patients infected wit
✍ Mario M. Leitao Jr; Paul White; Bernadette Cracchiolo 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 216 KB 👁 1 views

## Abstract ## BACKGROUND. The objective of this study was to compare the human immunodeficiency virus (HIV) viral load (VL) and CD4 counts in patients infected with HIV with and without cervical cancer. The authors hypothesized that HIV‐positive women with cervical cancer would have a greater ris